Omalizumab: Difference between revisions
(added stub + cat) |
(more from mast cell page) |
||
| Line 1: | Line 1: | ||
{{Stub}} | {{Stub}} | ||
Omalizumab (Xolair) is a medication originally designed to reduce sensitivity to allergens and is used for treating | '''Omalizumab''' (Xolair) is a medication originally designed to reduce sensitivity to allergens and is used for treating chronic idiopathic [[urticaria]] and allergic [[asthma]]. It is a potential treatment for [[Mast cell activation syndrome|mast cell disorders]]. | ||
== Mechanism == | |||
It is a monoclonal antibody that binds to free [[immunoglobulin E]] (IgE) in the blood and interstitial fluid and to membrane-bound form of IgE (mIgE) on the surface of mIgE-expressing [[B cell]]s. It inhibits the binding of IgE to FcεRI on [[mast cell]]s and [[basophil]]s by binding to an antigenic epitope on IgE that overlaps with the site to which FcεRI binds. In this sense, it is a potent [[mast cell stabilizer]]. | It is a monoclonal antibody that binds to free [[immunoglobulin E]] (IgE) in the blood and interstitial fluid and to membrane-bound form of IgE (mIgE) on the surface of mIgE-expressing [[B cell]]s. It inhibits the binding of IgE to FcεRI on [[mast cell]]s and [[basophil]]s by binding to an antigenic epitope on IgE that overlaps with the site to which FcεRI binds. In this sense, it is a potent [[mast cell stabilizer]]. | ||
== Research on mast cell disorders == | |||
In a study of 55 French patients with mast cell disorders treated with omalizumab, 43 patients achieved a "best response" and 76.7% of the responding patients achieved a persistent response (three months or longer.)<ref name=":2">{{Cite web|url=https://www.aaaai.org/global/latest-research-summaries/New-Research-from-JACI-In-Practice/mast-cells|title=A new therapy to calm down mast cells|last=|first=|authorlink=|last2=|first2=|authorlink2=|date=April 9, 2019|website=American Academy of Allergy, Asthma & Immunology|archive-url=|archive-date=|dead-url=|access-date=July 28, 2019}}</ref> Median time to first response was 2 months and median time to best response was 6 months. One severe adverse event occurred, with researchers suggesting this recommends initiating treatment in hospital, but otherwise found the safety profile acceptable.<ref name=":2" /> | |||
==References== | ==References== | ||
[[Category:Potential treatments]] | [[Category:Potential treatments]] | ||
Revision as of 03:24, July 29, 2019
 | This article is a stub. |
Omalizumab (Xolair) is a medication originally designed to reduce sensitivity to allergens and is used for treating chronic idiopathic urticaria and allergic asthma. It is a potential treatment for mast cell disorders.
Mechanism[edit | edit source]
It is a monoclonal antibody that binds to free immunoglobulin E (IgE) in the blood and interstitial fluid and to membrane-bound form of IgE (mIgE) on the surface of mIgE-expressing B cells. It inhibits the binding of IgE to FcεRI on mast cells and basophils by binding to an antigenic epitope on IgE that overlaps with the site to which FcεRI binds. In this sense, it is a potent mast cell stabilizer.
Research on mast cell disorders[edit | edit source]
In a study of 55 French patients with mast cell disorders treated with omalizumab, 43 patients achieved a "best response" and 76.7% of the responding patients achieved a persistent response (three months or longer.)[1] Median time to first response was 2 months and median time to best response was 6 months. One severe adverse event occurred, with researchers suggesting this recommends initiating treatment in hospital, but otherwise found the safety profile acceptable.[1]
References[edit | edit source]
- ↑ 1.0 1.1 "A new therapy to calm down mast cells". American Academy of Allergy, Asthma & Immunology. April 9, 2019. Retrieved July 28, 2019. Cite has empty unknown parameter:
|dead-url=(help)
